Protocol Ledger

NCT03443024 · Phase II · COMPLETED

A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

Interventional Phase II clinical trial protocol NCT03443024 sponsored by Eli Lilly and Company in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-01-30 Enrollment: 280 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03443024
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)280 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03443024
Protocol FieldVerified Registry Value
NCT IdentifierNCT03443024
Consolidated Lead SponsorEli Lilly and Company
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment280 participants (ACTUAL)
Registered Start Date2018-01-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI